SCHEMBL29854881

SCHEMBL29854881

C=CCCCCOC(=O)Nc1ccc2c(C(C)=O)nn(CC(=O)OC(C)(C)C)c2c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 4/20 0.34
▸ RAB9A P51151 3/20 0.34
▸ LMNA P02545 1/20 0.34
▸ BRD4 O60885 2/20 0.33
▸ EPHX2 P34913 1/20 0.33
▸ NPC1 O15118 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ CASP3 P42574 1/20 0.33
▸ SENP8 Q96LD8 1/20 0.33
▸ SENP7 Q9BQF6 1/20 0.33
▸ SENP6 Q9GZR1 1/20 0.33
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ TRPV1 Q8NER1 1/20 0.32
▸ ACSS2 Q9NR19 1/20 0.31
▸ CFD P00746 3/20 0.31
▸ MET P08581 4/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20487891 0.97 HPGD (0.35) HPGDRAB9ALMNABRD4EPHX2
SCHEMBL20488754 0.89 HPGD (0.37) HPGDRAB9ALMNAEPHX2NPC1
SCHEMBL20488749 0.86 RAB9A (0.38) HPGDRAB9ALMNANPC1SMN1; SMN2
SCHEMBL20488757 0.85 QPCT (0.39) BRD4CFD
SCHEMBL25965640 0.83 RAB9A (0.37) HPGDRAB9ALMNAEPHX2NPC1
SCHEMBL29854911 0.80 DGAT2 (0.41) HPGDBRD4SMN1; SMN2KDM4EALDH1A1
SCHEMBL20488336 0.80 DGAT2 (0.41) HPGDBRD4SMN1; SMN2KDM4EALDH1A1
SCHEMBL29855032 0.79 DYRK1A (0.37) BRD4CFD
SCHEMBL23589763 0.78 RAB9A (0.38) HPGDRAB9ALMNAEPHX2NPC1
SCHEMBL29855040 0.77 MTNR1A (0.30) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12297205-B2 Macrocyclic compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2025-05-13 — — US disclosed
US-20240059702-A1 MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2024-02-22 — — US disclosed
US-11718626-B2 Macrocyclic compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2023-08-08 — — US disclosed
EP-3589287-B1 MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS INC (US) 2022-09-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718626-B2 Macrocyclic compounds for treatment of medical disorders CFD, TFPI, CFH HPGD 115/4885RAB9A 2435/4885LMNA 1759/4885
US-12297205-B2 Macrocyclic compounds for treatment of medical disorders CFD, TFPI, CFH HPGD 115/4885RAB9A 2435/4885LMNA 1759/4885
US-20240059702-A1 MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS CFD, TFPI, CFH HPGD 115/4885RAB9A 2435/4885LMNA 1759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback